-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Caris Life Sciences, Raises Price Target to $36

Benzinga·11/06/2026 21:25:59
Listen to the news
Citigroup analyst Albert Hu maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and raises the price target from $28 to $36.